Clinical Trial Update: Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating olorofim (F901318) for invasive fungal infections in participants with no remaining treatment options has completed and results have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Fungal Infections

Drugs mentioned

• Olorofim (olorofim)

Snippet

Sponsor: F2G Biotech GmbH | Conditions: Invasive Fungal Infections | Phase 2 | Status: COMPLETED | Results posted: 2024-07-10